Disease Domain | Count |
---|---|
Neoplasms | 4 |
Hemic and Lymphatic Diseases | 2 |
Endocrinology and Metabolic Disease | 2 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Target |
Mechanism P2Y14 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK9 inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism CDK4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2025 |
Sponsor / Collaborator |
Start Date30 Dec 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Compound 16 (China Pharmaceutical University) ( P2Y14 ) | Acute Myeloid Leukemia More | Preclinical |
CDDD11-8 ( CDK9 x FLT3 ) | Acute Myeloid Leukemia More | Preclinical |
2-94 (University of South Australia) ( CDK4 ) | Ovarian Cancer More | Preclinical |
CN117003679 ( CYP24A1 ) | Neoplasms More | Discovery |
MKI-9 ( Protein kinases ) | Neoplasms More | Pending |